Dragon Pharma Cardiogen 20 mg – Synthetic Tetrapeptide for Cardiovascular Research
✔ Synthetic AEDR tetrapeptide bioregulator ✔ Studied for cardioprotective mechanisms ✔ Regulates fibroblast activity & apoptosis ✔ USA domestic shipping available
Dragon Pharma Cardiogen 20 mg is a synthetic tetrapeptide bioregulator with the amino acid sequence Ala-Glu-Asp-Arg (AEDR). This compound has been investigated in experimental models for its potential cardiovascular support properties, including regulation of fibroblast activity, protection of cardiac myocytes from programmed cell death, and promotion of tissue repair mechanisms.
Each vial contains 20 mg of lyophilized Cardiogen in a 2 mL format, requiring reconstitution with bacteriostatic water before use. Cardiogen represents a targeted research tool for investigating the molecular pathways involved in cardiac tissue preservation and recovery. For related research compounds, explore our peptides category and specifically SS-31 50 mg for mitochondrial function studies.
What Makes Cardiogen Valuable in Research?
Cardiogen belongs to a class of short-chain peptides known for their tissue-specific bioregulatory properties. The AEDR sequence has been studied for its ability to influence cellular processes relevant to cardiovascular health, including the modulation of fibroblast activity, inhibition of apoptosis in cardiac muscle cells, and support of regenerative responses in cardiac tissue.
Researchers value Cardiogen for its targeted approach to studying cardiac physiology. Its defined sequence and mechanism of action make it a practical tool for investigating the molecular basis of myocardial protection and repair. For investigators exploring broader cardiovascular research applications, MOTS-C offers complementary avenues in metabolic and cardiac function studies.
Current scientific literature on Khavinson peptides, including Cardiogen, can be accessed through the PubMed database, where researchers can review peer-reviewed studies on their biological activity and experimental applications.
Key Research Applications for Dragon Pharma Cardiogen
- ✔ Investigation of cardiac fibroblast regulation
- ✔ Evaluation of anti-apoptotic mechanisms in cardiomyocytes
- ✔ Research on myocardial tissue repair and regeneration
- ✔ Studies of peptide bioregulation in cardiovascular models
- ✔ Preclinical models of cardiac protection and recovery
For Research Purposes Only
Cardiogen 20 mg is intended for research use only and is not approved for human consumption. Proper handling, reconstitution, and experimental protocols are essential for reliable results. For studies on vascular health, TB 500 provides additional research avenues in tissue repair and angiogenesis.
Technical Details
Peptide Type
Synthetic Tetrapeptide
Peptide Sequence
Ala-Glu-Asp-Arg (AEDR)
Peptide Length
4 Amino Acids
Molecular Formula
C₁₈H₃₁N₇O₉
Molecular Weight
489.5 g/mol
Research Status
Experimental
Dosage & Usage Guidelines
For research and laboratory use only. Dragon Pharma Cardiogen 20 mg is a synthetic tetrapeptide bioregulator. Proper reconstitution, handling, and experimental design are essential for obtaining reliable data.
Reconstitution Protocol
- ✔ Use sterile bacteriostatic water for injection
- ✔ Add appropriate volume to achieve desired concentration
- ✔ Swirl gently to dissolve – do not shake vigorously
- ✔ Store reconstituted solution at 2–8°C
Reconstitute the lyophilized powder using bacteriostatic water to a concentration suitable for your research protocol. The 20 mg format allows for flexible dosing across a range of experimental models. Always use aseptic technique during preparation to maintain peptide integrity.
Typical Research Parameters
In research settings, Cardiogen is typically administered via subcutaneous or intraperitoneal injection. Dosing schedules and concentrations vary widely depending on the experimental design, animal model, and specific research objectives.
- ✔ Commonly used in cardiovascular protection studies
- ✔ Often combined with histological and molecular analysis
- ✔ Used to investigate apoptosis inhibition and fibroblast regulation
- ✔ Research models include cardiac injury and recovery paradigms
Factors to Consider in Research Protocols
- Short-chain peptide with specific bioregulatory properties
- Reconstitution stability is limited; prepare fresh solutions for each use
- Individual variation in response may be observed across subjects
- Storage conditions significantly impact peptide stability
Research note: Cardiogen is part of the Khavinson peptide class, known for their tissue-specific bioregulatory effects. Its short AEDR sequence provides a defined molecular tool for investigating cardiac protection mechanisms, including the regulation of apoptosis and fibroblast activity in myocardial tissue.
Shipping & Product Authenticity
USA Domestic
4–5 business days
International
13–15 business days
Order Processing
24–48 business hours
Tracking
Tracking number provided
Direct Supply & Discreet Delivery
This product is supplied through the official Dragon Pharma distribution chain and shipped in original manufacturer packaging. The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details.
What to Expect
- ✔ Orders are processed after payment confirmation
- ✔ USA Domestic shipping is typically faster when local stock is selected
- ✔ International orders include tracking, though update frequency may vary by destination
- ✔ Multiple warehouses may result in separate shipments when applicable
Authenticity support: official Dragon Pharma presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
Verified Supply
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
Store the lyophilized powder at controlled room temperature (15–25°C) in a dry, dark place, away from direct light and moisture. The unopened vial should be kept in its original packaging to maintain stability.
After reconstitution, store the solution at 2–8°C and use within 14 days. Do not freeze. Discard any unused portion after the recommended storage period. Before use, inspect the solution and avoid use if it appears cloudy, discolored, or contains particulate matter, or if the vial or seal is compromised.
Keep out of reach of children. Follow proper handling and sterile injection practices during research use.
Proper storage conditions help maintain product stability and consistent performance across the product's shelf life.
Frequently Asked Questions
What is Dragon Pharma Cardiogen 20 mg used for?
Cardiogen is used in research to investigate cardiovascular protection mechanisms, including regulation of fibroblast activity, inhibition of apoptosis in cardiac muscle cells, and promotion of tissue repair in cardiac models.
What is the amino acid sequence of Cardiogen?
Cardiogen has the amino acid sequence Ala-Glu-Asp-Arg (AEDR), a short-chain peptide known for its tissue-specific bioregulatory properties in cardiovascular research.
How do I reconstitute Cardiogen 20 mg powder?
Reconstitute the lyophilized powder with sterile bacteriostatic water for injection. Add the appropriate volume, swirl gently until fully dissolved, and avoid vigorous shaking to preserve peptide integrity.
What is the shelf life of Cardiogen after reconstitution?
Reconstituted Cardiogen should be stored at 2–8°C and used within 14 days. Discard any unused solution after this period to ensure stability and research accuracy.
Is Dragon Pharma Cardiogen 20 mg lab-tested?
Third-party laboratory testing for Cardiogen 20 mg is currently pending. Batch-specific COA data will be published once analytical testing is completed and verified.
No reviews found
Please log in to write Cardiogen 20 mg review.
